We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
New study data confirming that attention-deficit/hyperactivity disorder (ADHD) drug NRP104, being developed by New River Pharmaceuticals and Shire Pharmaceuticals, is less likely to be abused than other amphetamine-based ADHD stimulants has one industry analyst predicting the federal government will give it a more favorable classification.
A recently published study shows multiple sclerosis (MS) drug Copaxone, marketed by Teva Pharmaceutical and sanofi-aventis, reduced annual relapse rates 75 percent in patients who switched to Copaxone from MS treatment Betaseron, the drugmakers said June 20.
Northfield Laboratories agreed June 16 to purchase a building that will house its first commercial facility for producing PolyHeme, the company's human hemoglobin-based oxygen carrier.
Changing the pH of anti-cancer drugs can greatly reduce the harm they cause to normal cells while still allowing them to effectively kill cancer cells, reducing side effects for chemotherapy patients, according to a study published in the latest issue of the journal ACS Chemical Biology.
The combined use of two statin drugs resulted in the largest reduction of cholesterol levels ever seen in a clinical trial, researchers at the Methodist DeBakey Heart Center in Houston say.
Neurocrine Biosciences believes it may have to provide the FDA with additional data to get agency approval to market its insomnia drug and is requesting a meeting with the FDA to clarify what’s required.
Eli Lilly’s antidepressant Prozac does not lower risk of relapse or help anorexia nervosa patients who have restored their body weight maintain it, according to a study published in the June 14 issue of the Journal of the American Medical Association.
The FTC’s proposed study of the economic effects of authorized generics has some interested groups raising such concerns as the impact the practice has on prices, availability and competition.